Tumor markers in pancreatic cancer: 2013 Highlights from the "2013 ASCO Annual Meeting". Chicago, IL, USA; May 30 - June 4, 2013

Journal of the Pancreas

Volumn 14, Issue 4, 2013, Pages 318-321

  Ajay Shah, Urvi ^a   Wasif Saif, Muhammad ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

CA 19 9 antigen; Pancreatic neoplasms; Prognosis

Indexed keywords

ANG2 PROTEIN; ANGIOGENIC FACTOR; CA 19-9 ANTIGEN; CYTOKINE; GEMCITABINE; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 6; INTERLEUKIN 8; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR BB; SOMATOMEDIN BINDING PROTEIN 3; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRAMETINIB; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER PREVENTION; CANCER PROGNOSIS; CANCER SCREENING; CANCER SURGERY; CONSENSUS DEVELOPMENT; DISEASE FREE SURVIVAL; FALSE POSITIVE RESULT; HUMAN; LAPAROSCOPY; MEDICAL EDUCATION; MEDICAL SOCIETY; METASTASIS; ONCOLOGY; OVERALL SURVIVAL; PANCREAS CANCER; PREDICTIVE VALUE; PREOPERATIVE EVALUATION; PROTEIN BLOOD LEVEL; SALVAGE THERAPY; TREATMENT INDICATION; TREATMENT OUTCOME;

CA-19-9 ANTIGEN; DISEASE PROGRESSION; HUMANS; PANCREATIC NEOPLASMS; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84880077745     PISSN: 15908577     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Bilimoria, K.Y., et al., Validation of the 6th edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database. Cancer, 2007. 110(4): p. 738-44.
2. American Cancer Society. Cancer Facts & Figures 2013. Atlanta: American Cancer Society; 2013
3. Bussom, S. and M.W. Saif, Methods and rationale for the early detection of pancreatic cancer. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010. JOP: Journal of the pancreas, 2010. 11(2): p. 128-30.
4. Koprowski, H., et al., Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic cell genetics, 1979. 5(6): p. 957-71.
5. Tempero, M.A., et al., Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer research, 1987. 47(20): p. 5501-3.
6. Ballehaninna, U.K. and R.S. Chamberlain, The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. Journal of gastrointestinal oncology, 2012. 3(2): p. 105-19.
7. Sugiura, T., et al., Serum CA 19-9 is a significant predictor among preoperative parameters for early recurrence after resection of pancreatic adenocarcinoma. Journal of gastrointestinal surgery: official journal of the Society for Surgery of the Alimentary Tract, 2012. 16(5): p. 977-85.
8. Lee, K.J., et al., Serum CA 19-9 and CEA levels as a prognostic factor in pancreatic adenocarcinoma. Yonsei medical journal, 2013. 54(3): p. 643-9.
9. Humphris, J.L., et al., The prognostic and predictive value of serum CA 19.9 in pancreatic cancer. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO, 2012. 23(7): p. 1713-22.
10. Haas, M., et al., Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analysis of patients receiving palliative chemotherapy. Journal of cancer research and clinical oncology, 2013. 139(4): p. 681-9.
11. Nakai, Y., et al., A retrospective analysis of early CA 19-9 progression in salvage chemotherapy for refractory pancreatic cancer. Journal of Clinical Oncology 31, 2013 (suppl; abstr e15146)
12. Chiorean, E. G., et al., CA 19-9 decrease at 8 weeks as a predictor of overall survival (OS) in a randomized phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients with metastatic pancreatic cancer (MPC.) Journal of Clinical Oncology 31, 2013 (suppl; abstr 4058)
13. Tsai S., et al, Association of decline in serum CA 19-9 after neoadjuvant therapy with improved survival among borderline resectable pancreatic cancer patients. Journal of Clinical Oncology 31, 2013 (suppl; abstr e15082)
14. Heymach J., et al, Circulating cytokines and angiogenic factors (CAF) as markers of clinical response in the study of trametinib (T) plus gemcitabine (G) versus placebo (P) plus gemcitabine for patients (pts) with untreated metastatic adenocarcinoma of the pancreas (MEK113487). Journal of Clinical Oncology 31, 2013 (suppl; abstr 4042)